Neurol. praxi. 2023;24(2):98-102 | DOI: 10.36290/neu.2022.073

Ocular manifestations of disease associated with the presence of antibodies to myelin oligodendrocyte glycoprotein

MUDr. Barbora Beroušková, MUDr. Kateřina Myslík Manethová, Ph.D., FEBO
Oční oddělení Fakultní Thomayerovy nemocnice, Praha

Myelin oligodendrocyte glycoprotein antibody-positive disease (MOGAD) is a relatively new diagnostic entity that has emerged from the spectrum of neuromyelitis optica disorder (NMOSD), formerly also known as Devic's disease. This inflammatory autoimmune demyelinating disease affects the optic nerve, spinal cord and some other structures of the central nervous system. One of the cardinal manifestations in adult patients is optic neuritis. In children, the disease manifests as acute demyelinating encephalomyelitis (ADEM). The main diagnostic criteria are visible signs of CNS demyelination and detection of serum MOG-IgG antibodies. An attack of optic neuritis is accompanied by a severe visual deficit, which in most cases is at the level of counting fingers. A relatively good adjustment of visual functions is typical. We can quantify the severity of the eye impairment using OCT (optical coherence tomography), where, despite the good adjustment of visual functions, we find a significant loss of nerve fibers. Changes are seen in the optic nerve (pRNFL - peripapillary retinal nerve fiber layer) and macular area - ganglion cells (GCL - ganglion cell layer) and inner plexiform layer (IPL - inner plexiform layer). As a result of an attack of optic neuritis, there is a varying degree of impairment of visual functions and the optic nerve. The severity of the disability is dependent on the timely initiation of therapy and the setting of chronic therapy to prevent further attacks of the disease. Interdisciplinary cooperation between a neurologist and an ophthalmologist is very important in the diagnosis of optic neuritis.

Keywords: neuromyelitis optica spectrum disorders (NMOSD), myelin oligodendrocyte glycoprotein antibody­‑associated disease (MOGAD), optic neuritis, multiple sclerosis, optical coherence tomography (OCT).

Received: November 16, 2022; Revised: November 16, 2022; Accepted: November 16, 2022; Prepublished online: November 17, 2022; Published: April 21, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Beroušková B, Myslík Manethová FEBO K. Ocular manifestations of disease associated with the presence of antibodies to myelin oligodendrocyte glycoprotein. Neurol. praxi. 2023;24(2):98-102. doi: 10.36290/neu.2022.073.
Download citation

References

  1. Akaishi T, Nakashima I, Takeshita T, et al. Different etiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol. 2016;299:152-57. Go to original source... Go to PubMed...
  2. Bartels F, Lu A, Oertel FC, et al. Clinical and neuroimaging findings in MOGAD­‑MRI and OCT. Clin Exp Immunol. 2021;206:266-81. Go to original source... Go to PubMed...
  3. Cobo­‑Calvo A, Ruiz A, Rollot F, et al.; and Ofsep study groups. Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody­‑Associated Disease. Ann Neurol. 2021; 89:30-41. Go to original source... Go to PubMed...
  4. Costello F, Chen JJ. The role of optical coherence tomography in the diagnosis of afferent visual pathway problems: a neuroophthalmic perspective. Handb Clin Neurol. 2021;178:97-113. Go to original source... Go to PubMed...
  5. Diblik P, Kuthan P, Sklenka P. Neuritida zrakového nervu u roztroušené sklerózy mozkomíšní - typické obrazy a úskalí diferenciální diagnostiky. Neurol. praxi. 2011;12(3):156-59.
  6. Filippatou AG, Mukharesh L, Saidha S, et al. AQP4-IgG and MOG­‑IgG Related Optic Neuritis­‑Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta­‑Analysis. Front Neurol. 2020;11:540156. Go to original source... Go to PubMed...
  7. Graf J, Mares J, Barnett M, et al. Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1', Neurol Neuroimmunol Neuroinflamm. 2021;8. Go to original source... Go to PubMed...
  8. Hacohen Y, Banwell B. Treatment Approaches for MOG­‑Ab­‑Associated Demyelination in Children. Curr Treat Options Neurol. 2019;21:2. Go to original source... Go to PubMed...
  9. Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein­‑immunoglobulin G (MOG­‑IgG) optic neuritis. Curr Opin Neurol. 2020;33:47-54. Go to original source... Go to PubMed...
  10. Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid­‑sparing maintenance immunotherapy for MOG­‑IgG associated disorder. Neurology. 2020;95:e111-e20. Go to original source... Go to PubMed...
  11. Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin Oligodendrocyte Glycoprotein Antibody­‑Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018;195:8-15. Go to original source... Go to PubMed...
  12. Chen JJ, Huda S, Hacohen Y, et al. Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody­‑Associated Disease. JAMA Neurol. 2022;79:518-25. Go to original source... Go to PubMed...
  13. Chen JJ, Sotirchos ES, Henderson AD, et al. OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody­‑associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. Mult Scler Relat Disord. 2022;58:103525. Go to original source... Go to PubMed...
  14. Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. Nervenarzt. 2018;89:1388-99. Go to original source... Go to PubMed...
  15. Otradovec J, CSc. 2003. Klinická neurooftalmologie. 2003.
  16. Jitprapaikulsan J, Chen JJ, Flanagan EP, et al. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. Ophthalmology. 125:1628-37. Go to original source... Go to PubMed...
  17. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem. 1999;72:1-9. Go to original source... Go to PubMed...
  18. Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG­‑antibody disease: a UK study. Brain. 2017;140:3128-38. Go to original source... Go to PubMed...
  19. Katz U, Achiron A, Shere Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2017;6:257-9. Go to original source... Go to PubMed...
  20. Klistorner A, Arvind H, Nguyen T, et al. Axonal loss and myelin in early ON loss in postacute optic neuritis. Ann Neurol. 2008;64:325-31. Go to original source... Go to PubMed...
  21. Lízrová Preiningerová J, et al. Optická koherenční tomografie v neurologii. Maxdorf: Praha, 2020.
  22. Jirásková N. Neurooftalmologie - minimum pro praxi. 2001.
  23. O'Connell KA, Hamilton­‑Shield M, Woodhall S. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody­‑positive NMOSD and MOG antibody­‑positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry. 2020;91:1126-28. Go to original source... Go to PubMed...
  24. Oertel FC, Kuchling J, Zimmermann H, et al. Microstructural visual system changes in AQP4-antibody­‑seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm. 2017;4:e334. Go to original source... Go to PubMed...
  25. Oertel FC, Specovius S, Zimmermann HG, et al. Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurol Neuroimmunol Neuroinflamm. 2021;8. Go to original source... Go to PubMed...
  26. Ojha PT, Aglave VB, Soni G, et al. Myelin Oligodendrocyte Glycoprotein (MOG) Antibody­‑Associated CNS Demyelination: Clinical Spectrum and Comparison with Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder. Neurol India. 2020;68:1106-14. Go to original source... Go to PubMed...
  27. Pérez Bartolomé F, Garcîa Vasco L, Abreu Ventura N, et al. Diagnosis Approach of Optic Neuritis. J Neurol Neurophysiol. 2015.
  28. Svozílková P, et al. Diagnostika a léčba očních zánětů. Maxdorf: Praha, 2006.
  29. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15:89-102. Go to original source... Go to PubMed...
  30. Sechi E, Cacciaguerra L, Chen JJ, et al. Myelin Oligodendrocyte Glycoprotein Antibody­‑Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol. 2022;13:885218. Go to original source... Go to PubMed...
  31. Stiebel­‑Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6:e572. Go to original source... Go to PubMed...
  32. Wilejto M, Shroff M, Buncic JR, et al. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology. 2006;67:258-62. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.